Vertigo/dizziness accounts for more than 2% of all consultations in general practice\textsuperscript{1,4} and emergency departments.\textsuperscript{5} Vertigo is 1 of the 10 most common symptoms for which patients seek medical advice. Most of these patients are elderly people, with an increased prevalence up to the age of 50 years; approximately 30% of 65-year-old people experience recurrent episodes of vertigo.\textsuperscript{6,7} Disturbances in balance increase the risk of falling considerably and, therefore, the rapid and appropriate treatment of dizziness/vertigo is necessary to prevent any associated increase in morbidity or mortality.

Classification of Vertigo

Different classifications of vertigo exist, sometimes making a common communication platform within the medical community difficult. From a practical point of view, vertigo can be divided into specific (true) vertigo, originating in the vestibular system; and nonspecific and nonvestibular vertigo/dizziness, formerly subdivided into disequilibrium, presyncope, or light-headedness. Vertigo is a multisensory syndrome (Figure 1); when originating in the vestibular system, it is often subdivided into disequilibrium, presyncope, or light-headedness. Vertigo is a multisensory syndrome and not a disease entity.\textsuperscript{2} Diagnostic and therapeutic strategies to treat vertigo/dizziness need to be customized to the individual patient’s needs.

Epidemiology

In epidemiological studies, patients experiencing nonvestibular vertigo/dizziness within the group of all vertigo cases range from approximately 20% to 80%. Research in primary care settings usually reports a higher percentage of nonvestibular vertigo: 88% of the cases tend to be chronic, and 44% of those patients visit the GP more than once (≤15 times). Referral rates to specialists (otorhinolaryngologists and neurologists) are low.\textsuperscript{16-19} In an investigation of 7609 patients diagnosed as having vertigo in 138 German GP practices over 18 months, only
19.8% were classified as having vestibular vertigo (4.3%, BPPV; 2.0%, Meniere disease; 0.6%, vestibular neuritis; and 12.9%, other vertigo); 80.2% of the patients were diagnosed as having nonvestibular vertigo/dizziness. The referral rate of these patients to specialists was only 3.9%. Also, only 13.7% of patients received medical treatment, either with conventional drugs (eg, betahistine, dimenhydrinate and cinnarizine combinations, sulpiride, and flunarizine) or bioregulatory medications (eg, Vertigoheel). However, in a report from a specialty clinic, this ratio is inverted, with two-thirds of the patients diagnosed as having specific vertigo and one-third diagnosed as having other kinds of vertigo. Therefore, non-specific and nonvestibular vertigo seems to be the most challenging form of vertigo/dizziness for the primary care physician. Because of an unfavorable risk to benefit ratio of long-term conventional drug treatment in nonspecific vertigo, GPs often seek complementary and alternative medicine–orientated approaches to care for these patients.

### Diagnostic Approach

Acute vertigo/dizziness is often self-limiting. However, the severity of the illness can substantially decrease the quality of life. In acute care settings, the most relevant decision to be made by the health care practitioner is if vertigo/dizziness is accompanied by so-called red flag symptoms. A selection of these symptoms includes the following:• new/severe headache or neck pain• blurred vision• hearing loss• difficulties speaking• unconsciousness• falling or problems walking• ataxia• paraesthesia• bradycardia/tachycardia• angina pectoris

These symptoms should be taken seriously. Further emergency measures, including prompt referral to a specialist or an emergency department, have to be taken. Careful medical history taking and a clinical evaluation are usually sufficient to guide diagnosis and initiate treatment in patients without red flag symptoms (Figure 2). Also, there is spontaneous resolution potential for vertigo/dizziness. Nevertheless, after the initial 3-month compensation period, acute cases can become chronic. The most relevant questions for assessing a patient with dizziness/vertigo are as follows:

• Can you describe the sensation you are feeling during the attack? (Avoid giving influencing examples.)

Rotational vertigo with the sign of nystagmus at rest is usually vestibular vertigo.
How long do your vertigo attacks last?
Benign paroxysmal postural vertigo usually lasts only for seconds after head motion, whereas Meniere disease is usually episodic (from 20 minutes to a few hours). Long-lasting and disabling vertigo is often a sign of acute loss of vestibular function, as is seen in vestibular neuritis or other forms of loss in vestibular function.

Do you have associated symptoms?
If vertigo is accompanied by a headache, be aware of migraine-associated vertigo. Tinnitus and reduced hearing capacity of low frequencies are characteristic of Meniere disease. Anxiety symptoms are seen in patients with phobic vertigo. Fainting is characteristic in individuals with orthostatic hypotension, cardiac arrhythmias, or reactive hypoglycemia.

What triggers the attack?
Head motion can trigger BPPV, and special situations (eg, taking an elevator) can trigger phobic vertigo.

In elderly patients with chronic symptoms, further diagnosis is often not helpful. A watchful waiting strategy can be considered, but symptoms tend to persist.10,11 A thorough medical history regarding therapeutic drug use is necessary because many drugs (eg, antihypertensive agents, psychotropic agents, and others) can cause dizziness in elderly patients. Therefore, a careful decision has to be made regarding the risks and benefits of drugs in this population group. In addition to discontinuing the medication, detoxification measures might be helpful in this situation. Vestibular rehabilitation22 and complementary and alternative medicine–orientated approaches can be beneficial to this group.

Bioregulatory Medical Approach

Because vertigo is a multisensory syndrome of various origins and of different pathological features, the attempt to treat vertigo with a conventional, single-target, single-molecule approach is limited. Different parts of the peripheral and central nervous systems are involved in vertigo/dizziness, and no specific approach from conventional medicine has been absolutely effective. Furthermore, conventional medications have adverse effects that prohibit the long-term use of these drugs in patients with chronic vertigo. A multi-targeted and multicomponent approach, as delivered by bioregulatory therapy with low-dose/ultra–low-dose medications, might be an efficient therapeutic option. Treatment goals are symptomatic, specific, or rehabilitative. The basic medication for patients with any kind of symptomatic vertigo is a combination preparation, Vertigoheel. This prep-

Figure 2. Algorithm for Diagnosing Vertigo for the General Practitioner (adapted from Labuguen9)
Refrsh Your Homotoxicology

The preparation contains *Anamirta cocculus*, *Conium maculatum*, *Ambra grisea*, and *Petroleum rectificatum*. Vertigoheel is indicated for various types of vertigo and has been investigated thoroughly in experimental settings on microcirculation and in clinical studies. In acute care settings, Vertigoheel might be administered parenterally. Under supervision by a treating physician, Vertigoheel is usually given for 6 to 8 weeks and can be easily switched from the parenteral to the oral form. If vertigo can be linked to a specific vestibular disease, the pathogenesis of this disease should be considered in the treatment plan. The focus is on the 3-pillar approach in bioregulatory medicine. For example, BPPV is thought to be caused by otoliths in one of the semicircular canals of the vestibular system and is routinely treated by positioning maneuvers as standard treatment. Otoliths are a manifestation of the deposition phase and, therefore, a course of basic detoxification and drainage might be worth considering from a bioregulatory medicine point of view to prevent relapses. Vestibular neuritis, a further example of a specific disease in vestibular vertigo, is linked to viral infections in some cases. This means that patients with vestibular neuritis might be treated with Engystol or Traumeel for immunoregulatory purposes. Meniere disease, a type of episodic vertigo with endolymphatic hydrops within the vestibular system, might benefit from basic and advanced detoxification/drainage measures. Because accompanying symptoms are often troublesome to patients with acute vertigo, patients can be treated optionally with Vomitusheel for nausea, often found in those with peripheral vertigo; and with Gelsemium-Homoaccord or Spigelon for headache. Vertigo can be a stress-related symptom, and relaxation methods and low-dose medications (eg, Nervoeheel or Neurexan) might help. An example of a bioregulatory therapy protocol for vertigo is shown in the Table (Meniere disease).

### Table: Bioregulatory Treatment Protocol for Meniere Disease

<table>
<thead>
<tr>
<th>DET-Phase</th>
<th>Basic and/or Symptomatic</th>
<th>Regulation Therapy*</th>
<th>Optional</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurodermal Impregnation</td>
<td>• Vertigoheel</td>
<td>D&amp;D • Basic and advanced detoxification and drainage where appropriate (see text)</td>
<td>• Vomitusheel (in the presence of nausea)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IM • Engystol (only in cases in which virus infection contributes to Meniere disease)</td>
<td>• Nervoeheel/Neurexan (if stress related)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>COS • Coenzyme compositum • Ubichinon compositum (see text)</td>
<td>• Cerebrum compositum (in the presence of cognitive decline)</td>
</tr>
</tbody>
</table>

**Notes:** Vestibular rehabilitation, including habituation exercise or balance (mind/body) therapy, is helpful.

**Dosages:** Please refer to the general dosage recommendation of the specific country.

Abbreviations: COS, cell and organ support; D&D, detoxification and drainage; DET, Disease Evolution Table; IM, immunomodulation.

*Antihomotoxic regulation therapy consists of a 3-pillar approach: D&D, IM, and COS.

*For basic detoxification and drainage, the Detox-Kit consists of Lymphomyosot, Nux vomica-Homoaccord, and Berberis-Homoaccord.

*For advanced supportive detoxification and drainage, therapy consists of Hepar compositum (liver), Solidago compositum (kidney), and Thyreoidea compositum (connective tissue).
can lead to dizziness. Sclerosis of cerebral blood vessels also might be involved. However, it is not clear to what extent structural changes of the macrocirculation and microcirculation are the cause of dizziness in elderly patients. It would be interesting to investigate if drugs from the catalyst medication group (eg, Coenzyme compositum or Ubichinon compositum) or Composita medications (eg, Cerebrum compositum) would have additional functional effects on the sensory system in elderly patients. Given the potency of these drugs, this approach is not recommended routinely but might be considered on an individual basis.

Additional Measures

Postural maneuvers are helpful because they generally trigger the compensation and adaptation processes of the central nervous system to the pathological conditions. They should be performed as soon as possible; as a rule of thumb, they are feasible under appropriate precautions and supervision and only with patients that will not vomit when their head is moved. During the acute phases of vertigo, the patient should be advised to avoid circumstances in which a vertigo/dizziness attack can cause harm (eg, when driving, handling machines, swimming, or diving). If vertigo/dizziness persists for longer than 3 months, a long-term course is likely and vestibular rehabilitation is always an option. This includes repositioning treatments and balance therapy. Head movement exercises while sitting or standing are the option of choice because they decrease vertigo/dizziness, improve standing balance, and increase independence in activities of daily living.

Conclusions

Dizziness/vertigo is a common problem in clinical care. Individualized therapy is mandatory in acute and chronic cases. Bioregulatory medical therapy is exceptionally promising for this multisensory syndrome because it is a multitargeted therapy and does not suppress the compensation mechanisms needed for symptomatic recovery.

References: